BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30715147)

  • 1. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.
    Bi Y; Liu J; Furmanski B; Zhao H; Yu J; Osgood C; Ward A; Keegan P; Booth BP; Rahman A; Wang Y
    Ann Oncol; 2019 Apr; 30(4):644-651. PubMed ID: 30715147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
    Long GV; Tykodi SS; Schneider JG; Garbe C; Gravis G; Rashford M; Agrawal S; Grigoryeva E; Bello A; Roy A; Rollin L; Zhao X
    Ann Oncol; 2018 Nov; 29(11):2208-2213. PubMed ID: 30215677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types.
    Zhao X; Shen J; Ivaturi V; Gopalakrishnan M; Feng Y; Schmidt BJ; Statkevich P; Goodman V; Gobburu J; Bello A; Roy A; Agrawal S
    Ann Oncol; 2020 Feb; 31(2):302-309. PubMed ID: 31959348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers.
    Bei D; Osawa M; Uemura S; Ohno T; Gobburu J; Roy A; Hasegawa M
    Cancer Sci; 2020 Feb; 111(2):528-535. PubMed ID: 31773815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Benefit-Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors.
    Sheng J; Zhang J; Baudelet C; Roy A
    J Clin Pharmacol; 2021 Aug; 61(8):1045-1053. PubMed ID: 33501654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
    Lala M; Li TR; de Alwis DP; Sinha V; Mayawala K; Yamamoto N; Siu LL; Chartash E; Aboshady H; Jain L
    Eur J Cancer; 2020 May; 131():68-75. PubMed ID: 32305010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.
    Zhao X; Suryawanshi S; Hruska M; Feng Y; Wang X; Shen J; Vezina HE; McHenry MB; Waxman IM; Achanta A; Bello A; Roy A; Agrawal S
    Ann Oncol; 2017 Aug; 28(8):2002-2008. PubMed ID: 28520840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
    Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers.
    Osawa M; Hasegawa M; Bello A; Roy A; Hruska MW
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):705-715. PubMed ID: 30666395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.
    Puszkiel A; Bianconi G; Pasquiers B; Balakirouchenane D; Arrondeau J; Boudou-Rouquette P; Bretagne MC; Salem JE; Declèves X; Vidal M; Kramkimel N; Guegan S; Aractingi S; Huillard O; Alexandre J; Wislez M; Goldwasser F; Blanchet B
    Br J Cancer; 2024 May; 130(11):1866-1874. PubMed ID: 38532102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
    Augustin M; Reich K; Yamauchi P; Pinter A; Bagel J; Dahale S; You R; Bruin G; Djimopoulos J; Paguet B; Charef P; Patekar M; Keefe D
    Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors.
    Zhao Y; Sanghavi K; Roy A; Murthy B; Bello A; Aras U; Vezina H
    Clin Pharmacol Ther; 2024 Mar; 115(3):488-497. PubMed ID: 38115195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma.
    Samlowski W; Robert NJ; Chen L; Schenkel B; Davis C; Moshyk A; Kotapati S; Poretta T; Weber JS
    Cancer Med; 2023 Feb; 12(3):2378-2388. PubMed ID: 35880244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization and toxicity patterns of 2-weekly (Q2W) versus 4-weekly (Q4W) nivolumab for treatment of adjuvant and metastatic melanoma at BC cancer.
    Truong J; Yeung SST; Kletas V; de Lemos M; Schaff K; Nakashima L
    J Oncol Pharm Pract; 2023 Sep; ():10781552231199048. PubMed ID: 37654194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy.
    Agrawal S; Feng Y; Roy A; Kollia G; Lestini B
    J Immunother Cancer; 2016; 4():72. PubMed ID: 27879974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posology.
    Sanghavi K; Vuppala P; Ivaturi V; Hamuro L; Roy A; Suryawanshi S
    CPT Pharmacometrics Syst Pharmacol; 2021 Jul; 10(7):748-759. PubMed ID: 33955714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of dosing strategy for pembrolizumab for oncology indications.
    Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
    J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P).
    Langley RG; Papp K; Gooderham M; Zhang L; Mallinckrodt C; Agada N; Blauvelt A; Foley P; Polzer P;
    Br J Dermatol; 2018 Jun; 178(6):1315-1323. PubMed ID: 29405255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
    Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
    Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flat dose regimen of toripalimab based on model-informed drug development approach.
    Li L; Qu J; Song M; Zhao Q; Yang Y; Tan X; Hu Y; Li J; Lin Y; Feng H; Yao S; Keegan P; Chen M
    Front Pharmacol; 2022; 13():1069818. PubMed ID: 36712659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.